Cashed up PFIZER seeking @Oncology, vaccines, rare diseases and internal medicine

From USA's ENDPOINTS NEWS today

Albert Bourla has some plans for Pfizer's huge Covid cash haul.
By John CarrollEditor & Founder

Hint: 'Acquisitions are very much in the cards'John CarrollEditor & FounderToday was Pfizer CEO Albert Bourla’s chance to relish the market success of its Covid vaccine and drug and what a fresh flow of $54 billion-plus from the pandemic franchise this year can do for the company.

First on the list?
The BD team is buckling down to pick up the pace for more deals in the year ahead.This is clearly Aamir Malik’s turn to shine, after taking the BD reins from John Young last summer as he completed a 34-year career run at Pfizer.“In terms of the top-line, we are going to be incredibly flexible,” Malik told analysts today. “We have said repeatedly that we are most interested in compounds that have the potential to be real breakthroughs. And this can take the form of later-stage clinical development as well as earlier-stage medical innovation.”

Oncology, vaccines, rare diseases and internal medicine are among the core focuses in R&D, and Malik said they’ll continue to be active “where we have the scientific chops to make good scientific choices and add real value.”